TruSight Oncology 500 is NGS assay supports identification of all relevant DNA and RNA variants implicated in various solid tumor types. It accurately measures microsatellite instability (MSI) and tumor mutational burden (TMB).
- Pan-cancer biomarker content aligned with key guidelines and clinical trials
- DNA + RNA assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB
- Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay
- Enable In-House Comprehensive Genomic Profiling
The TruSight Hereditary Cancer Panel content was selected based on feedback from key opinion leaders on genetic risk assessment.
- Includes 10,341 probes that target 113 genes related to cancer predisposition.
- TruSight Hereditary Cancer Panel includes 125 SNPs. Of these, 48 are ID SNPs and 77 are used for polygenic risk scoring (PRS).
- In combination with Illumina DNA Prep with Enrichment (enzyme-based DNA fragmentation), it enables genetic labs to prepare hybrid capture sequencing libraries in 6.5 hours with limited hands on time of ~2 hours.
- Accommodates flexible workflows and is compatible with different sources of samples such as genomic DNA, saliva (Oragene tubes) or blood (Flex Lysis Reagent).
- Allows for maximum flexibility for batching from 2 to 256 samples.
- Indexes are available for up to 384 samples to allow for flexible batch sizes and scalability across all Illumina benchtop sequencers (iSeq 100, MiSeq, MiniSeq, and NextSeq).
The AmpliSeq Childhood Cancer Panel for Illumina provides a targeted resequencing solution for comprehensive evaluation of somatic variants associated with childhood and young adult cancers, including leukemias, brain tumors, and sarcomas
- Target multiple variant types across 203 genes, including hotspots, single nucleotide variants (SNVs), indels, copy number variants (CNVs), and gene fusions
- Sequencing libraries in a single day with as little as 10 ng high-quality DNA or RNA from blood, bone marrow, or FFPE samples
- Detect somatic mutations down to 5% frequency using local or cloud-based analysis
The AmpliSeq for Illumina BRCA Panel is a targeted resequencing assay for research of somatic and germline variants across BRCA1 and BRCA2 genes. BRCA1 and BRCA2 are human tumor suppressor genes that, when carrying specific mutations, have been implicated in an increased risk for breast and ovarian cancers.
- Target all exonic regions and flanking intronic sequences of BRCA1 and BRCA2
- Sequencing-ready libraries in a single day from as little as 1 ng of high quality or 10 ng of FFPE input samples
- Detect somatic mutations as low as 5% variant allele frequency using local or cloud based analysis
The AmpliSeq for Illumina Focus Panel is a targeted resequencing assay. Using the Focus Panel, researchers can analyze both DNA and RNA concurrently.
- Target biomarkers across 52 genes relevant to solid tumors
- Sequencing-ready libraries in a single day from as little as 1 ng of high quality or 10 ng of FFPE input samples
- Detect somatic mutations down to 5% frequency using local or cloud-based analysis
The Myeloid Panel enables concurrent analysis of both DNA and RNA from blood and bone marrow samples in a single assay to study biomarkers associated with hematologic malignancies. The panel covers relevant targets for these major myeloid disorders: AML, MDS, MPN, CML, CMML, and JMML.
- Targets biomarkers across 69 genes including challenging targets such as CEBPA and FLT3-ITDs
- Sequencing-ready libraries in a single day from as little as 10 ng high-quality DNA and RNA
- Detect somatic mutations down to 5% frequency using local or cloud-based analysis